Literature DB >> 30218317

Why harmonization is needed when using FDG PET/CT as a prognosticator: demonstration with EARL-compliant SUV as an independent prognostic factor in lung cancer.

Benjamin Houdu1, Charline Lasnon2,3, Idlir Licaj4, Guy Thomas5, Pascal Do6, Anne-Valerie Guizard7, Cédric Desmonts1, Nicolas Aide8,9.   

Abstract

BACKGROUND: To determine EARL-compliant prognostic SUV thresholds in a mature cohort of patients with locally advanced NSCLC, and to demonstrate how detrimental it is to use a threshold determined on an older-generation PET system with a newer PET/CT machine, and vice versa, or to use such a threshold with non-harmonized multicentre pooled data.
MATERIALS AND METHODS: This was a single-centre retrospective study including 139 consecutive stage IIIA-IIIB patients. PET data were acquired as per the EANM guidelines and reconstructed with unfiltered point spread function (PSF) reconstruction. Subsequently, a 6.3 mm Gaussian filter was applied using the EQ.PET (Siemens Healthineers) methodology to meet the EANM/EARL harmonizing standards (PSFEARL). A multicentre study including non-EARL-compliant systems was simulated by randomly creating four groups of patients whose images were reconstructed with unfiltered PSF and PSF with Gaussian post-filtering of 3, 5, and 10 mm. Identification of optimal SUV thresholds was based on a two-fold cross-validation process that partitioned the overall sample into learning and validation subsamples. Proportional Cox hazards models were used to estimate age-adjusted and multivariable-adjusted hazard ratios (HRs) and their 95% confidence intervals. Kaplan-Meier curves were compared using the log rank test.
RESULTS: Median follow-up was 28 months (1-104 months). For the whole population, the estimated overall survival rate at 36 months was 0.39 [0.31-0.47]. The optimal SUVmax cutoff value was 25.43 (95% CI: 23.41-26.31) and 8.47 (95% CI: 7.23-9.31) for the PSF and for the EARL-compliant dataset respectively. These SUVmax cutoff values were both significantly and independently associated with lung cancer mortality; HRs were 1.73 (1.05-2.84) and 1.92 (1.16-3.19) for the PSF and the EARL-compliant dataset respectively. When (i) applying the optimal PSF SUVmax cutoff on an EARL-compliant dataset and the optimal EARL SUVmax cutoff on a PSF dataset or (ii) applying the optimal EARL compliant SUVmax cutoff to a simulated multicentre dataset, the tumour SUVmax was no longer significantly associated with lung cancer mortality.
CONCLUSION: The present study provides the PET community with an EARL-compliant SUVmax as an independent prognosticator for advanced NSCLC that should be confirmed in a larger cohort, ideally at other EARL accredited centres, and highlights the need to harmonize PET quantitative metrics when using them for risk stratification of patients.

Entities:  

Keywords:  EARL accreditation program; FDG; Harmonization; Non-small-cell lung cancer; PET/CT; Prognosticator; Survival

Mesh:

Substances:

Year:  2018        PMID: 30218317     DOI: 10.1007/s00259-018-4151-8

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  27 in total

1.  Confidence intervals for the effect of a prognostic factor after selection of an 'optimal' cutpoint.

Authors:  Norbert Holländer; Willi Sauerbrei; Martin Schumacher
Journal:  Stat Med       Date:  2004-06-15       Impact factor: 2.373

Review 2.  Standards for PET image acquisition and quantitative data analysis.

Authors:  Ronald Boellaard
Journal:  J Nucl Med       Date:  2009-04-20       Impact factor: 10.057

3.  A simulation study of cross-validation for selecting an optimal cutpoint in univariate survival analysis.

Authors:  D Faraggi; R Simon
Journal:  Stat Med       Date:  1996-10-30       Impact factor: 2.373

4.  The use of fused PET/CT images for patient selection and radical radiotherapy target volume definition in patients with non-small cell lung cancer: results of a prospective study with mature survival data.

Authors:  Michael P Mac Manus; Sarah Everitt; Mike Bayne; David Ball; Nikki Plumridge; David Binns; Alan Herschtal; Deborah Cruickshank; Mathias Bressel; Rodney J Hicks
Journal:  Radiother Oncol       Date:  2013-03-28       Impact factor: 6.280

5.  Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial.

Authors:  Ali Salavati; Fenghai Duan; Bradley S Snyder; Bo Wei; Sina Houshmand; Benjapa Khiewvan; Adam Opanowski; Charles B Simone; Barry A Siegel; Mitchell Machtay; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-07-08       Impact factor: 9.236

6.  Patterns of abnormal FDG uptake by various histological types of non-small cell lung cancer at initial staging by PET.

Authors:  C Y Wong; R Nuñez; P Bohdiewicz; R J Welsh; G W Chmielewski; K P Ravikrishnan; J C Hill; S E Pursel; D Fink-Bennett; H Balon; C Dickinson; H J Dworkin
Journal:  Eur J Nucl Med       Date:  2001-11

Review 7.  Role of 18F-FDG PET in assessment of response in non-small cell lung cancer.

Authors:  Rodney J Hicks
Journal:  J Nucl Med       Date:  2009-04-20       Impact factor: 10.057

8.  Does PET SUV Harmonization Affect PERCIST Response Classification?

Authors:  Elske Quak; Pierre-Yves Le Roux; Charline Lasnon; Philippe Robin; Michael S Hofman; David Bourhis; Jason Callahan; David S Binns; Cédric Desmonts; Pierre-Yves Salaun; Rodney J Hicks; Nicolas Aide
Journal:  J Nucl Med       Date:  2016-06-09       Impact factor: 10.057

Review 9.  EANM/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies.

Authors:  Nicolas Aide; Charline Lasnon; Patrick Veit-Haibach; Terez Sera; Bernhard Sattler; Ronald Boellaard
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06-16       Impact factor: 9.236

10.  EANM/EARL FDG-PET/CT accreditation - summary results from the first 200 accredited imaging systems.

Authors:  Andres Kaalep; Terez Sera; Wim Oyen; Bernd J Krause; Arturo Chiti; Yan Liu; Ronald Boellaard
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-12-01       Impact factor: 9.236

View more
  9 in total

1.  How Often Do We Fail to Classify the Treatment Response with [18F]FDG PET/CT Acquired on Different Scanners? Data from Clinical Oncological Practice Using an Automatic Tool for SUV Harmonization.

Authors:  Maria Vittoria Mattoli; Maria Lucia Calcagni; Silvia Taralli; Luca Indovina; Bruce S Spottiswoode; Alessandro Giordano
Journal:  Mol Imaging Biol       Date:  2019-12       Impact factor: 3.488

2.  Comparison between tumour metabolism derived from 18F-FDG PET/CT and accurate cytogenetic stratification in newly diagnosed multiple myeloma patients.

Authors:  Yannick Silva; Jean-Marc Riedinger; Marie-Lorraine Chrétien; Denis Caillot; Jill Corre; Kévin Guillen; Alexandre Cochet; Claire Tabouret-Viaud; Romaric Loffroy
Journal:  Quant Imaging Med Surg       Date:  2021-10

3.  Maximum standardized uptake value of primary tumor (SUVmax_PT) and horizontal range between two most distant PET-positive lymph nodes predict patient outcome in inoperable stage III NSCLC patients after chemoradiotherapy.

Authors:  Olarn Roengvoraphoj; Lukas Käsmann; Chukwuka Eze; Julian Taugner; Arteda Gjika; Amanda Tufman; Indrawati Hadi; Minglun Li; Erik Mille; Kathrin Gennen; Claus Belka; Farkhad Manapov
Journal:  Transl Lung Cancer Res       Date:  2020-06

Review 4.  Influences on PET Quantification and Interpretation.

Authors:  Julian M M Rogasch; Frank Hofheinz; Lutz van Heek; Conrad-Amadeus Voltin; Ronald Boellaard; Carsten Kobe
Journal:  Diagnostics (Basel)       Date:  2022-02-10

5.  Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors.

Authors:  Romain-David Seban; Laura Mezquita; Arnaud Berenbaum; Laurent Dercle; Angela Botticella; Cécile Le Pechoux; Caroline Caramella; Eric Deutsch; Serena Grimaldi; Julien Adam; Samy Ammari; David Planchard; Sophie Leboulleux; Benjamin Besse
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-11-21       Impact factor: 9.236

6.  Moving the goalposts while scoring-the dilemma posed by new PET technologies.

Authors:  Julian M M Rogasch; Ronald Boellaard; Lucy Pike; Peter Borchmann; Peter Johnson; Jürgen Wolf; Sally F Barrington; Carsten Kobe
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-05-14       Impact factor: 9.236

7.  The ratio between the whole-body and primary tumor burden, measured on 18F-FDG PET/CT studies, as a prognostic indicator in advanced non-small cell lung cancer.

Authors:  Felipe Renê Alves Oliveira; Allan de Oliveira Santos; Mariana da Cunha Lopes de Lima; Ivan Felizardo Contrera Toro; Thiago Ferreira de Souza; Bárbara Juarez Amorim; Aristoteles Souza Barbeiro; Elba Etchebehere
Journal:  Radiol Bras       Date:  2021 Sep-Oct

8.  What validation tests can be done by the clinical medical physicist while waiting for the standardization of quantitative SPECT/CT imaging?

Authors:  Hanna Piwowarska-Bilska; Aleksandra Supińska; Bożena Birkenfeld
Journal:  EJNMMI Phys       Date:  2022-02-05

9.  Radiomics model of dual-time 2-[18F]FDG PET/CT imaging to distinguish between pancreatic ductal adenocarcinoma and autoimmune pancreatitis.

Authors:  Zhaobang Liu; Ming Li; Changjing Zuo; Zehong Yang; Xiaokai Yang; Shengnan Ren; Ye Peng; Gaofeng Sun; Jun Shen; Chao Cheng; Xiaodong Yang
Journal:  Eur Radiol       Date:  2021-03-06       Impact factor: 5.315

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.